AstraZeneca (NYSE: AZN) adds 14,784 employee scheme shares

Rhea-AI Filing Summary

AstraZeneca PLC has admitted a further 14,784 ordinary shares of $0.25 each to trading on the Main Market of the London Stock Exchange. These shares were issued between 1 June 2026 and 30 June 2026 under the company’s existing block admission dated 29 January 2021.

Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,551,024,534. The new shares are fully fungible with existing ordinary shares and arise from the company’s employee share schemes.

Key Figures

New shares admitted: 14,784 shares Total shares in issue: 1,551,024,534 shares Nominal value per share: $0.25 per share +1 more

4 metrics

New shares admitted 14,784 shares Ordinary Shares of $0.25 each issued under employee schemes

Total shares in issue 1,551,024,534 shares Total ordinary shares following admission

Nominal value per share $0.25 per share Ordinary share denomination

Block admission date 29 January 2021 Existing block admission under which shares were admitted

Key Terms

block admission, employee share schemes, fungible, Public Offers and Admissions to Trading Regulations 2024 (POATRs), +1 more

5 terms

block admission regulatory

"admitted under a block admission dated 29 January 2021"

employee share schemes financial

"Admission of shares under the Company's employee share schemes from 1 June 2026"

fungible financial

"Fungibility | Fully fungible with existing Ordinary Shares"

Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.

Public Offers and Admissions to Trading Regulations 2024 (POATRs) regulatory

"in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs)"

LEI financial

"LEI | PY6ZZQWO2IZFZC3IOL08"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/01/2026 - 10:11 AM Accepted by SEC EDGAR 07/01/2026 - 10:10 AM Learn about SEC filing dates

FAQ

What does AstraZeneca (AZN) report in this July 2026 Form 6-K?

AstraZeneca reports the admission of 14,784 new ordinary shares to trading on the London Stock Exchange. These shares were issued under employee share schemes, increasing total shares in issue to 1,551,024,534 and are fully fungible with existing ordinary shares.

How many new AstraZeneca (AZN) shares were admitted to trading?

AstraZeneca admitted 14,784 additional ordinary shares of $0.25 each to trading. These shares were issued between 1 June 2026 and 30 June 2026 under existing block admission arrangements linked to the company’s employee share schemes on the London Stock Exchange.

What is AstraZeneca’s total share count after this admission?

After the admission of 14,784 further ordinary shares, AstraZeneca has 1,551,024,534 ordinary shares in issue. This total reflects all outstanding ordinary shares listed on the Main Market of the London Stock Exchange following the June 2026 issuances.

Why were the new AstraZeneca (AZN) shares issued and admitted?

The 14,784 new AstraZeneca ordinary shares were issued and admitted in connection with the company’s employee share schemes. They represent shares granted to employees and brought onto the Main Market of the London Stock Exchange under an existing block admission.

On which market are AstraZeneca’s new shares admitted to trading?

The new AstraZeneca ordinary shares are admitted to trading on the Main Market of the London Stock Exchange. They are fully fungible with the company’s existing ordinary shares, meaning they are identical in rights, listing status, and tradability for investors.

Over what period were the new AstraZeneca shares issued?

The 14,784 newly admitted AstraZeneca ordinary shares were issued between 1 June 2026 and 30 June 2026. They were then admitted to trading under a block admission originally dated 29 January 2021 covering issuances under employee share schemes.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of July 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Admission of Further Securities to Trading

1 July 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	14,784
d)	Total number of securities in issue following admission	1,551,024,534
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 June 2026 to 30 June 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 1 June 2026 up to 30 June 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 July 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary